Synosia Therapeutics
  • Home
  • About Us
    • The Company
    • Business Strategy
    • Senior Management
    • Board of Directors
    • Key Advisors
    • Scientific Advisory Board
    • Clinical Consultants
    • Investors
    •  
  • Development Areas
    • Parkinson's disease
    • Cognitive disorders
    • Drug dependency
    • Acute pain
    • Anxiety
    • Bipolar disorder
    • PTSD
    •  
  • Pipeline
  • Partnering
  • Events
  • Media
  • Contact

Press Releases

2008
2007
2008 Topic
30 July Starts Phase IIa Trial of Potential First Drug Therapy for Cocaine Dependence
   
24 July US Department of Defense Funds Trial Using Novel Compound from Synosia Therapeutics
   
10 June Starts Proof-of-Mechanism Trial for Nitisinone in Parkinson's Disease
   
3 June Begins Phase IIa Trial for Potential First-in-Class Treatment for Parkinson's Disease
   
31 March Announces Start of Ph II Efficacy Trial for Rufinamide SYN-111
   
4 February Appoints Chief Financial Officer to New Company Headquarters in Switzerland
   
22 January Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug Rufinamide

Media inquiries

Julie Walters
Tudor Reilly (Europe)
Tel: +44 (0) 1494 753990
Fax: +44 (0) 1494 753991
Mobile: +44 (0) 775 3626967
Email: julie.walters@tudor-reilly.com

Michele Parisi
Tudor Reilly (US)
Tel: +1 925 864 5028
Email: michele.parisi@tudor-reilly.com

Company Brochure

Download Company Brochure [pdf]

Copyright © 2007 
Synosia Therapeutics.
All rights reserved.